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Executive Summary

Executive Summary of the Early-Onset Breast
Cancer Evidence Review Conference
David Chelmow, MD, Mark D. Pearlman, MD, Amy Young, MD, Laura Bozzuto, MD, MS,
Sandra Dayaratna, MD, Myrlene Jeudy, MD, Mallory E. Kremer, MD, Dana Marie Scott, MD,
and Julia Sage O’Hara, MPH
Downloaded from https://journals.lww.com/greenjournal by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3y7wDLvMZ9kwodZ/WZ/8q6f71JqReofVlDlHEs5K0PkE= on 06/11/2020

The Centers for Disease Control and Prevention launched
the Bring Your Brave campaign to increase knowledge about
early-onset breast cancer, defined as breast cancer in women
aged 18–45 years. The American College of Obstetricians
and Gynecologists convened a panel of experts in breast
disease from the Society for Academic Specialists in General
Obstetrics and Gynecology to review relevant literature, validated tools, best practices, and practice guidelines as a first
step toward developing educational materials for women’s
health care providers about early-onset breast cancer. Panel
members conducted structured literature reviews, which
were then reviewed by other panel members and discussed
at an in-person meeting of stakeholder professional and
patient advocacy organizations in April 2019. This article
summarizes the relevant literature, existing guidance, and
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validated tools to guide health care providers in the prevention, early detection, and special considerations of earlyonset breast cancer. Substantive knowledge gaps were noted
and summarized to provide guidance for future research.
(Obstet Gynecol 2020;135:1457–78)
DOI: 10.1097/AOG.0000000000003889

E

arly-onset breast cancer is breast cancer occurring
in women aged 18–45 years. From 2012 to 2016,
early-onset breast cancer accounted for 10.3% of all
new female breast cancer cases. Furthermore, 5.6% of
breast cancer deaths in the United States occur in
women younger than 45 years.1 Approximately 15%
of breast cancer deaths result from breast cancers initially diagnosed before age 45 years.2 Because of the
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Table 1. Early-Onset Breast Cancer Evidence Review Conference Attendees
Attendee Role

Attendee Name(s)

Evidence review panelist

Stakeholder organization representative

ACOG staff

CDC representative and cooperative
agreement technical monitor
Consultant
Observer

David Chelmow, MD (Chair)
Amy Young, MD
Dana Scott, MD
Laura Bozzuto, MD
Mallory Kremer, MD
Mark Pearlman, MD
Myrlene Jeudy, MD
Sandra Dayaratna, MD
Allison W. Kurian, MD, MSc (National Comprehensive Cancer Network)
Amy L. Davis, DO, MS, FACP, FAAHPM (American College of Physicians)
Andrea Forman, MS, LCGC (National Society of Genetic Counselors)
Dana Smetherman, MD, MPH, MBA, FCAR (American College of Radiology)
Deborah Lindner, MD, FACOG (Bright Pink)
Edith P. Mitchell, MD, MACP, FCPP (National Medical Association)
Karen Smith, MD, MPH (American Society of Clinical Oncology)
Meredith Browne, PA-C (Association of Physician Assistants in Obstetrics and
Gynecology)
Mike Walsh, MD (American College of Medical Genetics)
Nancy Lee, MD (Black Women’s Health Imperative)
Robert Smith, PhD (American Cancer Society)
Rachel Gorham, MSN, WHNP-DC, AGN-BC (Nurse Practitioners in Women’s
Health)
Sarah Coles, MD (American Academy of Family Physicians)
Christopher M. Zahn, MD
Emily Greenwood
Julia S. O’Hara, MPH
Nancy O’Reilly, MHS
Temeika Fairley, PhD
Dana Trevas (Shea & Trevas, Inc.)
Christina R. Lachance, MPH (Health Resources Services Administration Office of
Women’s Health ex-officio to the CDC Advisory Committee on Breast Cancer in
Young Women)
Roshni Devchand, MPH (Hager Sharp)

ACOG, American College of Obstetricians and Gynecologists; CDC, Centers for Disease Control and Prevention.

young age of onset, women with early-onset breast
cancer have special survivorship issues, including contraception, management of menopausal symptoms,
fertility conservation, and pregnancy. The Centers
for Disease Control and Prevention (CDC) sponsored
development of educational material on early-onset
breast cancer. The educational material geared
towards patients, Bring Your Brave, is available on
the CDC website (https://www.cdc.gov/cancer/
breast/young_women/bringyourbrave/index.htm).
The CDC awarded the American College of Obstetricians and Gynecologists (ACOG) a grant to
develop accompanying health care provider material, available on line at www.acog.org/eobc.

METHODS
The American College of Obstetricians and Gynecologists convened an expert panel to identify the best

1458

Chelmow et al

evidence and practices from the literature, existing
relevant society guidelines, and available validated
specific or generalizable clinical tools. The panel was
recruited from the Society for Academic Specialists in
General Obstetrics and Gynecology to review and
summarize the evidence. Panel members were required
to have expertise in evidence review and synthesis.
Subspecialty expertise in breast disease was also
sought. Several of the panel members had completed
subspecialty fellowship training in breast disease. The
panel developed 10 separate research questions and
used the PICO criteria (P5patient, problem, or population; I5intervention; C5comparison, control, or
comparator; O5outcome[s]) to frame the literature
review. These questions form the organizing basis for
this executive summary.
Experts in literature searches from the ACOG
Resource Center searched the Cochrane Library,
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MEDLINE through Ovid, and PubMed for references
not indexed through MEDLINE from January 2010
to January 2019. Literature was organized by level of
evidence. Published guidelines were categorized separately from references. A primary reviewer was
assigned to each topic to review titles and abstracts,
then the entire manuscript when appropriate. Panel
members expanded the search criteria when necessary, either increasing the timeframe or broadening
the search to other populations, particularly when
inadequate evidence was found on the 18–45 years
age group. Reference lists from papers found in the
search were also reviewed. Internet searches with
standard search engines were performed to seek
guidelines, recommendations, and tools that might
not have been published in peer-reviewed publications. Relevant information was compiled into an evidence summary template. Completed templates were
then reviewed by a secondary reviewer and the primary and secondary reviewer worked together on revisions in response to the secondary reviewer’s
comments.
The American College of Obstetricians and
Gynecologists convened the Early-Onset Breast Cancer Evidence Review Conference in Washington, DC,
April 1–2, 2019, including the panel members and
representatives from stakeholder professional and
patient advocacy organizations (Table 1). Panel members presented their reviews to the convened group,
which discussed each section. Comments from the
discussion were integrated into the review summary
by the primary reviewer. The revised summaries were
sent to a tertiary reviewer for final review, and final
revisions were made by the primary reviewer. The
final reviews (see Appendices 1–10) were used to
develop the educational material.

EPIDEMIOLOGY, DEMOGRAPHICS,
AND SURVIVAL
Breast cancer is the most common form of cancer in
women and represents the second leading cause of
cancer death in women.3 National Cancer Institute
data from 2012 to 2016 indicated that 1.9% of new
breast cancer cases and 0.9% of cancer deaths
occurred among women aged 20–34 years, and
8.4% of new breast cancer cases and 4.7% of breast
cancer deaths occurred among women aged 35–44
years. Black women had the highest death rate at
28.1 per 100,000 persons. Although 5-year relative
survival rates were largely similar across age groups,
women younger than age 45 years had among the
lowest rates, second only to women aged 75 years
and older.1,4 See Table 1 in Appendix 1, available
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online at http://links.lww.com/AOG/B864, for breast
cancer incidence rates by age and race. See Table 2 in
Appendix 1 (http://links.lww.com/AOG/B864) for
breast cancer mortality rates by age and race.
Younger women tend to have more aggressive
and biologically unfavorable tumor subtypes than
older women and poorer survival in early stage
disease (stages I and II) when compared with women
older than 40 years. In advanced stages, younger
women have lower mortality, likely because of overall
general health.5 Although mortality trends have
improved in all women, young black women continue
to have higher mortality rates than other young
women with breast cancer, irrespective of stage or
hormone receptors. Annual hazard rates of death of
young black women are improving more slowly than
other races and ethnicities, suggesting less benefit
from advances in treatment. Poorer prognosis in black
women is thought to result from multiple factors,
including more aggressive tumors, access barriers,
and social determinants of health6 (see Appendix 1
[http://links.lww.com/AOG/B864] for complete evidence summary).

GENETIC RISK FACTORS
Cancer genes such as autosomal dominant single gene
pathogenic variants account for approximately 5–10%
of all cases of breast cancer. The BRCA1 and BRCA2
genes are the most common, representing more than
50% of all genes associated with early-onset breast
cancer. Women who carry pathogenic variants have
an increased lifetime risk of breast and other cancers
and are at higher risk of developing early-onset breast
cancer. BRCA pathogenic variants occur more frequently in certain populations (Table 2), most notably
in persons of Ashkenazi Jewish descent. The prevalence of BRCA1 and BRCA2 pathogenic variants is 1
in 40 (2.5%) in Ashkenazi Jews, compared with the
general population prevalence of 1 in 400–600.7,8 In
Ashkenazi Jews, three site-specific founder mutations
have been identified (185delAG and 5382insC in
BRCA1 and 6174delT in BRCA2), representing more
than 90% of the BRCA mutations.
In the United States, African American women
have a lower incidence of breast cancer than Caucasian women, but higher breast cancer mortality rates.9
The higher mortality rate seems to be associated with
two patterns: proportionally more African American
women are diagnosed before 50 years of age (30–40%
of all breast cancers in African American women)
compared with Caucasian women (approximately
20% of all breast cancer in Caucasian women), and
African American women have a twofold higher rate

Chelmow et al
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Table 2. Likelihood of Carrying a BRCA Pathogenic
Variant in Women With Breast Cancer
Race and Ethnicity
Caucasian
African American
Hispanic
Asian American
Ashkenazi Jewish

BRCA1

BRCA2

2–3%
1%
4%
Less than 1%
8–10%

2%
3%
No data
No data
1%

Data from Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L,
Coates RJ, et al. Prevalence and predictors of BRCA1 and BRCA2
mutations in a population-based study of breast cancer in white
and black American women ages 35–64 years. Cancer Res
2006;66:8297–308 and John EM, Miron A, Gong G, Phipps AI,
Felberg A, Li FP, et al. Prevalence of pathogenic BRCA1 mutation
carriers in 5 US racial/ethnic groups. JAMA 2007;298:2869–76.

of breast cancers that lack expression of the estrogen
receptor, progesterone receptor, and human epidermal
growth factor receptor 2, known as triple-negative
cancer.10 Triple-negative tumors are biologically more
active, with higher recurrence and mortality rates compared with most other breast cancer phenotypes.10,11
These differences do not appear to be due to higher
carriage rates of single gene mutations such as BRCA1
and BRCA2 alone.
Currently, population-based screening for BRCA
genes in the absence of other risk factors is not
broadly recommended, given their rarity and the
uncertain benefit of large-scale testing.12 Because Ashkenazi Jews have a 10-fold increased risk of carrying
a founder mutation in BRCA1 or BRCA2, consensus
guidelines recommend offering routine testing for the
three specific mutations.12,13
The National Comprehensive Cancer Network,
ACOG, the U.S. Preventive Services Task Force, the
American Society of Breast Surgeons, and the American
College of Medical Genetics provide recommendations
for risk assessment, referral to genetic counseling or
offering of genetic testing based on risk identification,
and management of men and women identified with
a genetic predisposition for early-onset breast cancer
(see Table 2 in Appendix 2, available online at http://
links.lww.com/AOG/B865). Common factors considered in risk assessment include the following:
1. Personal history of breast, ovarian, tubal, pancreatic, prostate, and other cancers and either early
age of onset of these cancers or other cancerspecific factors that increase the likelihood of carrying a pathogenic variant in a breast cancer
gene (eg, triple-negative tumors).
2. Family history of breast, ovarian, tubal, pancreatic, prostate, and other cancers suggesting an
autosomal dominant pattern of inheritance.
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In addition to BRCA1 and BRCA2, other important but less common autosomal dominant genes are
associated with early-onset breast cancer risk. Panel
testing has emerged in the past few years to assess
for possible gene alterations that have been implicated
in early-onset breast cancer. The specific panels are
usually defined by the laboratory offering the testing.
A woman identified with a pathogenic variant placing
her at increased risk for early-onset breast cancer can
undergo increased surveillance to detect breast cancer
at earlier stages, risk-reduction surgery, or chemoprophylaxis.13 Depending on the gene, surveillance may
start at an earlier age and include mammography,
magnetic resonance imaging (MRI), or both. The natural history of early-onset breast cancer is fairly well
understood for some genes (eg, BRCA), but there is
less complete understanding of the penetrance and
age of onset for those with non-BRCA genes associated
with breast cancer. Table 3 provides an overview of
common genes included in panel testing, along with
recommendations for surveillance and risk reduction
(see Appendix 2 [http://links.lww.com/AOG/B865]
for complete evidence summary).

FAMILY HISTORY OF EARLY-ONSET
BREAST CANCER
Assessment of family history is essential when evaluating young women accessing primary care. Understanding a woman’s family history of breast cancer
can identify individuals at elevated risk for hereditary
breast cancer or women who would benefit from
increased breast cancer surveillance. The American
College of Obstetricians and Gynecologists, the Society of Gynecologic Oncologists, the U.S. Preventive
Services Task Force, the National Institute of Health
Care Excellence, and the National Comprehensive
Cancer Network have published guidelines recommending assessment of family history and screening
for patients at increased risk of breast cancer. The
American College of Obstetricians and Gynecologists
states that screening should include at minimum a personal cancer history and first- and second-degree relatives’ cancer history that includes a description of the
type of primary cancer, the age of onset, and the lineage of the family member.14 The National Comprehensive Cancer Network clinical guidelines
recommend genetic assessment for all patients with
first- and second-degree relatives diagnosed with
breast cancer younger than age 50 years.13 The U.S.
Preventive Services Task Force recommends screening of women who have family members with breast,
ovarian, tubal, or peritoneal cancer using one of several screening tools designed to identify a family

Early-Onset Breast Cancer Executive Summary
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Table 3. Management of Women With Breast-Cancer–Associated Genes*
Screening Recommendation†
Gene

CBE‡

Mammography

Risk Reduction
Chemoprophylaxis
With Tamoxifen

MRI

BRCA1

Start: Age 25 years

Start: Age 30
years

Start: Age 25 years

Frequency:
Annual§
Start: Age 30
years

Frequency: Annual§

BRCA2

Frequency: Every
6–12 mo
Start: Age 25 years

Frequency: Every
6–12 months
No
recommendations
provided

Frequency:
Annual§
Start: Age 40
years

ATM

CHEK2

PALB2

PTEN

STK11

NF1

NBN

No
recommendations
provided

No
recommendations
provided

Start: Age 25 years

Frequency:
Annual
Start: Age 40
years

No
recommendations
provided

Frequency: Annual§

Consider start: 40 years

Frequency: Annual

Frequency:
Annual
Start: Age 30
years

Frequency: Annual

Frequency:
Annual#
Start: Age 30
years

Frequency:
Annual
Start: Age 40
years

Frequency:
Annual

Limited data to
support
tamoxifen.k

Discuss option of
RRM.¶

Limited data to
support
tamoxifen.k

Discuss option of
RRM.¶

Consider start: Age 40 years Insufficient data to
No data on the benefit
address efficacy of
of RRM, but may be
chemoprophylaxis.
considered based on
family history.
Frequency: Annual

Frequency:
Annual
Start: Age 30
years

Frequency: Every 6– Frequency:
12 months
Annual§
Start: Age ;25 years Start: Age ;25
years

Frequency: Every 6
months#
No
recommendations
provided

Start: Age 25 years

RRM

Consider start: 30 years

Start: Age 30 years
Frequency: Annual§
Start: Age 25 years

Frequency: Annual#

Insufficient data to
No data on the benefit
address efficacy of
of RRM, but may be
chemoprophylaxis.
considered based on
family history.

Insufficient data to
No data on the benefit
address efficacy of
of RRM, but may be
chemoprophylaxis.
considered based on
family history.k

Insufficient data to
Discuss option of
address efficacy of
RRM.k
chemoprophylaxis.

Insufficient data to
No data on the benefit
address efficacy of
of RRM, but may be
chemoprophylaxis.
considered based on
family historyk

Consider from 30–50 years Insufficient data to
No data on the benefit
address efficacy of
of RRM, but may be
chemoprophylaxis.
considered based on
family history.
Frequency: Annual
Consider Start: Age 40 years Insufficient data to
No data on the benefit
address efficacy of
of RRM, but may be
chemoprophylaxis.
considered based on
family history.
Frequency: Annual
(continued )
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Table 3. Management of Women With Breast-Cancer–Associated Genes* (continued )
Screening Recommendation†
Gene

CBE‡

Mammography
‡

Start: Age 30
years

Frequency: Every
6–12 months
No
recommendations
provided

Frequency:
Annual§
Start: Age 30
years

TP53 (P53) Start: Age 20 years

CDH1

Frequency:
Annual

Risk Reduction
MRI

Chemoprophylaxis
With Tamoxifen

RRM

Start: Age 20 years or earlier Insufficient data to
Discuss option of
if family history of
address efficacy of
RRM.¶
younger-onset breast
chemoprophylaxis.
cancer Frequency:
Annual§

Consider start: Age 30 years Insufficient data to
Discuss option of RRM
address efficacy of
(no data on
chemoprophylaxis.
benefit).¶
Frequency: Annual

Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk
Assessment: Breast and Ovarian V.3.2019. 2019 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN
Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of
NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are
a work in progress that may be refined as often as new significant data becomes available.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their
application or use in any way.
* CBE, clinical breast examination; MRI, magnetic resonance imaging; RRM, risk reduction mastectomy.
†
The age for starting breast screening may be earlier depending on earliest age of diagnosis in the family (if before age 30 years).
‡
Self-breast awareness (also called breast awareness) is recommended. It is defined as women being familiar with their breasts so they can
promptly report any changes to their health care provider.
§
Mammography and MRI are recommended to age 75; breast imaging beyond that age should be individualized.
k
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial HighRisk Assessment: Breast and Ovarian V.3.2019. National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed
August 12, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org.
¶
Mastectomy counseling includes degree of protection, reconstruction options, and risks of procedures.
#
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial HighRisk Assessment: Colorectal V.2.2019. National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 12,
2019. To view the most recent and complete version of the guideline, go online to NCCN.org.

history that may be associated with an increased risk
for potentially harmful mutations in breast cancer susceptibility genes (BRCA1 or BRCA2). Women with
positive screening results should receive genetic counseling and, if indicated after counseling, BRCA testing.12 Genetic counselors can help determine which
of the many available panels of genetic testing are
most appropriate and cost-effective.
Women with deleterious genetic mutations tend
to present with breast cancer at an earlier age.
However, some studies suggest that women with
a positive family history and no known genetic
mutation are at increased risk of developing breast
cancer and these cancers occur at an earlier age
compared with those in the general population who
did not have a known mutation.15–17 The Nurses’
Health Study and a systematic review and metaanalysis by Pharoah et al identified consistent findings.18,19 In the Nurses’ Health Study, women with
a family member diagnosed with breast cancer before
age 50 years had an increased risk for breast cancer
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compared with women of the same age who had family members diagnosed at older ages. Compared with
women with no family history, those whose mother
was diagnosed before age 50 years had an adjusted
relative risk (RR) of 1.69 (95% CI 1.39–2.05), and
those whose mother was diagnosed at 50 or older
had an RR of 1.37 (95% CI 1.22–1.53).18 Pharaoh
et al found that a history of breast cancer in at least
one first-degree relative resulted in RR estimates ranging from 1.2 to 8.8, with most studies showing RRs
between 2 and 3.19 The pooled risk estimate for having two affected first-degree relatives was 3.6 (95% CI
2.5–5.0).19 Genetic mutations were not factored out in
many of the older studies.
There are limited data on outcomes for women
with an elevated risk of breast cancer by family
history without an established familial genetic mutation. National guidelines consistently emphasize the
importance of gathering a thorough family history of
breast cancer. However, these guidelines are based on
limited data estimating lifetime and age-based breast
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cancer risk for women in families that do not have
identified genetic mutation carriers. Many of the
current guidelines are based on expert opinion and
studies of family history that were published before
the availability of genetic testing for mutations such as
BRCA1 and BRCA2.
There is general consensus that women with
a lifetime risk of breast cancer greater than 20%, as
determined by any model, are at high risk. Multiple
validated models can be used to determine the
probability of a genetic mutation, which increases the
risk of breast cancer. There is no consensus and there
are no data to support the recommendation of one
model over another.20 Currently, the National Comprehensive Cancer Network recommends that women
with an estimated lifetime risk of breast cancer of 20%
or higher, determined by models largely based on family history (eg, Breast and Ovarian Analysis of Disease
Incidence and Carrier Estimation Algorithm, Claus,
BRCAPRO, or Tyrer-Cuzick) should be offered annual
mammography screening starting at age 30 years and
annual breast screening by MRI starting at age 25
years13,21 (see Appendix 3, available online at http://
links.lww.com/AOG/B866, for complete evidence
summary). This is in contrast to screening recommendations for average risk women, which all recommend
screening with mammography alone, starting at age
40–50 years, depending on the source.14

UNDERSTANDING GENETIC COUNSELING
AND TESTING
There are at least moderate-quality data that risk
assessment, referral for genetic counseling, and
genetic testing provide net benefit in women at high
risk for early-onset breast cancer. These steps can
form the basis for intensive surveillance for early
detection or use of risk-reduction methods that have
proven effective in detecting breast cancer at an
earlier stage and decreasing mortality rates.12
The National Institutes of Health maintains
a periodically updated list of online resources designed to educate and assist health care providers on
various topics ranging from basic genetics, understanding risk assessment, criteria for referral to genetic
counseling, and interpretation of genetic test results.22
Other national societies have created genetics “toolkits” or published guidance to educate health care
providers on basic cancer genetics, risk assessment,
and referral recommendations23,24 (see Table 1 in
Appendix 4, available online at http://links.lww.
com/AOG/B867, for a list of useful websites).
Providers can also learn about these topics
through other mechanisms, such as continuing med-
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ical education and online learning. The depth and
detail of the material covered range from superficial
(eg, short “expert” videos) to online courses that take
place over several months. Very few online courses
provide a validated assessment of competency or certification. The content of specific training and assessment of competency for physicians who counsel
patients about genetic testing have not been
standardized.
The U.S. Preventive Services Task Force concluded that health care providers should assess risk
based on personal or family history and refer women
who screen positive to cancer genetic counselors.12 A
number of validated tools exist to determine who
should be referred for genetic testing,25–29 and several
professional specialty societies have developed lists of
indications for referral and testing.13,14,30 These tools
are specifically designed to evaluate who should be
referred for BRCA testing; however, because BRCA
carriers represent the greatest proportion of women
at genetic risk for early-onset breast cancer, these tools
are reasonable proxies for genetic screening for earlyonset breast cancer. These tools have been validated
in some populations (non-Hispanic white women),
and it is not known how the tools perform in nonwhite
populations. It remains unclear how frequently these
tools are used in practice by physicians. Evaluation
suggests that the tools miss a substantial proportion
of carriers.31,32 Interpretation of genetic test results
can be complex and usually requires a qualified individual who has specific training in cancer
genetics.12,33,34
A number of tools and calculators are used to
estimate lifetime invasive breast cancer risk, but not
necessarily the predicted age of onset (See Table 2 in
Appendix 4, http://links.lww.com/AOG/B867, for
a comparison of four commonly used riskassessment models: Tyrer-Cuzick, the Breast and
Ovarian Analysis of Disease Incidence and Carrier
Estimation Algorithm, Claus, and the modified Gail
model, also called the Breast Cancer Risk Assessment
Tool).
Numerous national consensus guidelines and
recommendations have been developed to assist
health care providers in communicating with patients
about referral to genetic counseling or testing for
early-onset breast cancer genes or both.13,14,30 Some
specialty societies have produced separate guidance
specifically addressing both the interpretation of
genetic test results and how to communicate these
results to patients.33 Some guidelines are frequently
updated,13 whereas others are periodically revised
(ie, every few years),12,14,30 resulting in guidance that
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may differ, causing confusion among health care providers and patients. All current guidelines recommend
that women should be screened for personal and family history of breast and other related cancers and
referred for genetic counseling or testing or both as
appropriate. In addition, all guidelines recommend
that determination for testing and pretest and posttest
counseling should be performed by individuals with
appropriate training. However, there is a shortage of
genetic counselors in the United States, which has
been identified as a barrier to effective counseling35,36
(see Appendix 4 [http://links.lww.com/AOG/B867]
for complete evidence summary).

DENSE BREASTS AND THE RISK OF EARLYONSET BREAST CANCER
Breast tissue is comprised of fibroglandular tissue and fat.
The fibroglandular tissue is a mixture of fibrous stroma
and ductal epithelium and appears denser or brighter on
mammography because the X-rays are not able to
penetrate at the same rate as fatty tissue. The Breast
Imaging-Reporting and Data System for mammography
developed by the American College of Radiology
includes a subjective assessment of how much fibroglandular tissue is present (see Table 1 in Appendix 5, available
online at http://links.lww.com/AOG/B868). As women
age, breast tissue typically becomes less dense. Most of
the data about breast density and cancer risk come from
women older than age 50 years. Dense breasts are present
in the majority of younger women.
A systematic review of risk for breast cancer in
women aged 40–49 years reported that extremely
dense breasts were associated with an increased risk
of breast cancer when compared with breasts with
scattered fibroglandular densities (RR 2.04, 95% CI
1.84–2.26).37 In a more recent case-control study of
213 Korean women with breast cancer, women who
had the highest breast density, described as 50% density or higher, after adjusting for multiple variable,
had an adjusted odds ratio of 2.98 (95% CI 0.99–
9.03) for breast cancer. The wide CIs in this nonsignificant finding is likely related to the small numbers
of included women and future studies should be monitored. Median age in the study was 51.5 years, with
45% of cancers diagnosed before age 50 years.38 Older studies are harder to interpret because they used
many different ways of characterizing breast density,
but in general, when comparing the most dense with
the least dense group, there appears to be an increased
risk of breast cancer, with RRs as high as 4.64 (95% CI
3.64–5.91) reported.39 As the majority of premenopausal women have dense breasts, it is not clear that
RRs estimated from comparisons of extremes of
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breast density categories are appropriate measures of
risk in this age group.
Dense breasts decrease the sensitivity of mammography because dense breast tissue appears radiopaque, similar to breast cancers, decreasing visual
contrast (“masking”). In women with extremely dense
breasts, mammography has 62% sensitivity for detection of breast cancer, compared with 88% sensitivity
for women with fatty breasts.40 One way to assess
delay in diagnosis is to determine the rate of interval
cancers, those cancers found between recommended
screening intervals after a normal mammogram. No
studies evaluating masking due to breast density have
exclusively evaluated women with early-onset breast
cancer. Most studies included large proportions of
women older than age 50 years, though women aged
40–49 years were included. More recent evidence suggests that dense breasts appear to be associated with at
least a twofold increased risk of interval cancers as
well as a worse prognosis, including larger tumor size
and more node-positive disease.41–43
Studies of adjunctive screening of women with
dense breasts with ultrasonography and MRI generally noted higher cancer detection rates and earlier
diagnoses, but also showed increase in biopsy for
benign lesions and increased healthcare costs, and no
study showed improvement in mortality (see Appendix 5 [http://links.lww.com/AOG/B868] for complete
evidence summary). The majority of women under
age 46 years have dense breasts, so any recommendations for additional screening in this age group would
require additional testing in a large number of women
whose baseline risk is low.
Most organizations, including ACOG and the
U.S. Preventive Services Task Force, do not recommend additional screening in women younger than
age 46 years with a normal mammogram and dense
breasts. The Society of Breast Imaging expresses
concern for a delay in diagnosis and later stage at
diagnosis of noncalcified breast cancers because of
dense breast tissue and suggests that ultrasonography
may be of benefit, provided the woman is willing to
accept an increased risk of false-positive results.44 The
National Comprehensive Cancer Network recommends that women with mammographically dense
breast tissue (heterogeneously or extremely dense tissue) be counseled about the risks and benefits of supplemental screening.45 Neither of these organizations
specifically address dense breasts in younger women.
Mandatory breast density reporting has been
enacted as legislation in an increasing number of
states. Many patients receive letters notifying them of
their breast density, and interpretation of these letters
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can be challenging for patients and health care
providers. In early 2019, Congress authorized the
U.S. Food and Drug Administration to amend the
Mammography Quality Standards Act of 1992 to
include mandatory breast density reporting at the
federal level. The public comment period for the
proposed changes to the legislation ended in June
2019, and final regulations should be forthcoming.
The American College of Obstetricians and Gynecologists recommends that health care providers comply
with state laws that require disclosure of breast density
in mammogram reports.46
Younger women with dense breasts and no other
risk factors can be counseled that dense breasts are
very common in this age group, and supplemental
screening methods are available. However, they are
not specifically recommended, have significant risk of
false positives, and have not been shown to change
outcome. When mammographic density in combination with other risk factors places the woman at aboveaverage risk, additional screening with ultrasonography may be warranted and a shared decision-making
model can be applied. Some breast cancer risk
calculators integrate breast density and can be used
to assess overall risk in these women (see Appendix 5
[http://links.lww.com/AOG/B868] for complete evidence summary).

EFFECT OF HEALTH HISTORY ON EARLYONSET BREAST CANCER
History of Proliferative Breast Disease
Many proliferative breast diseases increase the risk of
breast cancer, but the effect on early-onset breast
cancer risk is unknown. Atypical ductal hyperplasia
carries a more than 20% risk of ductal carcinoma in
situ (DCIS) or invasive malignancy at the time of
diagnosis, so it is typically excised.47 Both atypical
ductal hyperplasia and atypical lobular hyperplasia
are associated with a fourfold increased lifetime risk
of breast cancer.47–49 When atypical lobular hyperplasia is an incidental finding and there is concordance
between radiologic and pathologic findings regarding
the targeted biopsied lesion, it is less likely to be associated with a concurrent malignancy, so close monitoring is usually appropriate.48 Lobular carcinoma in
situ is not considered a preinvasive malignancy like
DCIS, but does significantly increase the lifetime risk
of breast cancer (RR 6.9–11, absolute risk 7.1% over
10 years).50,51 Pleomorphic lobular carcinoma in situ
may increase that risk even further.52 Radial scars are
characterized microscopically by a fibroelastic core
with radiating ducts and lobules. Radial scars and
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complex sclerosing lesions carry an 8–15% risk of
DCIS or invasive malignancy at the time of excision.47,53–57 Radial scars are usually managed by excisional biopsy.45
There are limited data with which to determine
the optimal screening strategy after atypical ductal
hyperplasia, atypical lobular hyperplasia, or lobular
carcinoma in situ. Breast MRI may improve breast
cancer detection over mammography alone, but it is
associated with more biopsies in this population.58
The National Comprehensive Cancer Network is
the only professional society with screening recommendations for those who have had atypical ductal
hyperplasia, atypical lobular hyperplasia, or lobular
carcinoma in situ45:
• Annual mammography (not before age 30 years).
Consider tomosynthesis.
• Consider annual breast MRI (not before age 25
years).
• Clinical breast examinations every 6–12 months.
• Engage in breast self-awareness (women should be
familiar with their breasts and report changes to
their health care provider promptly).

Past or Present Use of
Hormonal Contraception
There have been conflicting data regarding the effect of
hormonal contraception on breast cancer risk. A large
meta-analysis in 1996 revealed a small increased risk of
breast cancer among women with current or recent oral
contraceptive use (RR 1.07, SD 0.02, P,.001).59 Similar
findings were noted in a large cohort study in 2017 (RR
1.20, 95% CI 1.14–1.26).60 The absolute risk was quite
small (one additional breast cancer diagnosis for every
7,690 women using hormonal contraception each year).60
In both studies, breast cancer risk returned to baseline
5–10 years after discontinuing hormonal contraception.59,60 Most studies do not suggest an increased risk
of breast cancer among women using a levonorgestrel
intrauterine system (IUS) or depo-medroxyprogesterone
injections.60–64 There are limited data regarding the etonogestrel implant, but no study to date has demonstrated
an increased breast cancer risk.63
The risks of hormonal contraception must be
weighed against the health, social, and economic
consequences of unplanned pregnancy, as well as
the many noncontraceptive benefits of hormonal
contraception.65 The maternal mortality rate in the
United States in 2015 was 26.4 deaths per 100,000
pregnancies, which is comparable with the rate of
excess breast cancer diagnoses (13 [95% CI 10–16]/
100,000 person years) related to hormonal contraception suggested by the 2017 cohort study.60,66
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Hormonal contraception, particularly oral contraceptives, significantly decreases the risk of ovarian and
endometrial cancers.67,68 There are no screening
guidelines that specifically address exposure to hormonal contraception, so routine breast cancer screening is recommended in the absence of other risk
factors for early-onset breast cancer.

Past or Present Use of Fertility Treatments
Many fertility treatments cause an increase in circulating estrogen and progesterone levels, which theoretically could increase future breast cancer risk.69
Most studies have demonstrated no change or
a decreased risk of breast cancer after fertility treatments.59 Few studies specifically evaluated the risk of
early-onset breast cancer. Very limited data suggest
an increased risk of breast cancer among specific
populations, including women exposed to many
high-dose cycles of clomiphene citrate and women
undergoing in vitro fertilization before age 24
years.70,71 The American Society for Reproductive
Medicine states that there is “fair evidence that fertility drugs are not associated with an increased risk
of breast cancer (Grade B).”69 No screening guidelines specifically address fertility treatment exposure,
so routine breast cancer screening is recommended
in the absence of other risk factors for early-onset
breast cancer.

History of Radiation Exposure
Chest radiation therapy before age 30 years is a wellestablished risk factor for early-onset breast cancer.45,72 Treatments of concern include mantle radiation for Hodgkin’s lymphoma and moderate-dose
chest radiation therapy for non-Hodgkin’s lymphoma,
leukemia, bone malignancies, or pediatric solid tumors (eg, Wilms tumor, neuroblastoma, and softtissue sarcoma). The cumulative incidence of invasive
breast cancer in these patients is 13–20% by age 40–
45 years, similar to that seen among BRCA1 or BRCA2
mutation carriers.73–75 Risk is greatest among women
treated with 40 Gy or more, but all women treated
with 20 Gy or more are at increased risk for earlyonset breast cancer.73,74,76 This increased risk is evident 8–10 years after completion of radiation therapy
and does not plateau at any point after treatment.73–
75,77

Early initiation of breast cancer screening is
effective for reducing stage at diagnosis in this
population.73 Both mammography and breast MRI
are effective screening studies after chest radiation
therapy, but mammography has higher specificity.74,77–80 Multiple professional organizations have
published screening guidelines for women with a history of chest radiation therapy (Table 4). There are
limited data to suggest superiority of one screening
protocol over others. Shared decision making,

Table 4. Screening Guidelines for Women With a History of Chest Radiation (20 Gy or More Total) Before
Age 30

Intervention

National
Comprehensive Cancer
Network*

European Society of
Breast Cancer
Specialists†

International Late Effects of Childhood
Cancer Guideline Harmonization Group‡

Age to initiate screening Age 25 y or 10 y after
Age 30 y or 8 y after
Age 25 y or 8 y after radiation therapy
(use whichever is later)
radiation therapy
radiation therapy
Breast MRI frequency
Annual, starting at age 25 y Annual, starting at age 30 Annual MRI, mammography, or both (no
y
definitive recommendation)
Mammography
Annual, starting at age 30 Annual, starting at age 35
frequency
y; consider
y
tomosynthesis
Clinical breast
Every 6–12 mo
Not recommended
Not recommended
examination
Breast self-awareness
Encouraged
Not addressed in
Not addressed in guidelines
guidelines
MRI, magnetic resonance imaging.
* Data from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer Screening and Diagnosis.
V.1.2019. National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed August 12, 2019. To view the most
recent and complete version of the guideline, go online to NCCN.org.
†
Data from Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L, et al. The European Society of Breast Cancer Specialists
recommendations for the management of young women with breast cancer. Eur J Cancer 2012;48:3355–77.
‡
Data from Mulder RL, Kremer LC, Hudson MM, Bhatia S, Landier W, Levitt G, et al. Recommendations for breast cancer surveillance for
female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of
Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2013;14:e621–9.
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including the discussion of risks of false positives and
negatives, is recommended when deciding on a screening strategy.

Prior Breast or Ovarian Cancer
Breast cancer survivors remain at risk for a second
breast cancer, but the risk for a second early-onset
breast cancer among young breast cancer survivors is
unknown. Among survivors of any age without
a known cancer gene mutation, the risk of a second
breast cancer is approximately 3% and 7% at 10 and
15 years after diagnosis, respectively.81 There are no
data regarding risk of early-onset breast cancer in
women with ovarian cancer in childhood, adolescence, or early adulthood.
After breast cancer treatment, survivors require
clinical and imaging follow-up to assess for recurrence
and second malignancies. Both the National Comprehensive Cancer Network and the European Society of
Breast Cancer Specialists recommend annual mammograms starting 6–12 months after completion of
treatment.52,82 Breast MRI should be considered in
patients at high risk for a second cancer (eg, BRCA1
or BRCA2 mutation carriers)52,82 (see Appendix 6
[http://links.lww.com/AOG/B869] for complete evidence summary).

EFFECT OF HEALTH DISPARITIES ON EARLYONSET BREAST CANCER
Objective measures of health disparities are well
established, and health disparity populations83 exhibit
differences in rates of mammography screening, age
at breast cancer diagnosis, stage at time of diagnosis,
and rates of cancer treatment. African American
women are significantly more likely to experience
higher mortality from breast cancer compared with
white women (Fig. 1).84 Other health disparity groups,
such as American Indians and Alaska Natives, Asians,
Hispanics, and Native Hawaiians and other Pacific
Islanders, are affected but often inadequately studied,
as are sexual and gender minority persons.
The increased incidence of more-aggressive tumor
types only partly explains the survival gap for black
women.6,85 Social determinants of health, such as systemic racism, poverty, and the environment, greatly
affect cancer screening rates and outcomes.86 Health
literacy, childcare concerns, financial difficulties, and
transportation affect the likelihood of receiving preventive health services such as mammography.87,88
Geography is a particularly important factor.
Rural women are more likely to live in poor counties,
with greater barriers to accessing primary care.89 Poverty or lack of a regular primary care provider who
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recommends mammography is highly predictive of
not being screened.90,91 In general, poverty status correlates with more advanced stage at diagnosis, receiving less aggressive treatment, and higher risk of allcause mortality.92
Physical proximity to urban centers is not a panacea. In 2014, African American women with breast
cancer in Georgia living in isolated rural areas were
45% more likely to die than white women, whereas
African American women living in urban areas were
24% more likely to die than white women.92
Provider-level bias and discrimination in breast
cancer care treatment exist. For example, when
genetic testing is indicated, African American women
are less likely to be referred for genetic testing for
pathogenic variants than white women.93,94 African
American women are also less likely to receive any
type of lymph node surgery for axillary staging
overall.95
Women of lower socioeconomic status are
adversely affected by lack of health insurance coverage.89 Cost affects primary care utilization and is a factor
in patient decision making regarding mammography.96
By one estimate, up to 37% of the mortality difference
in breast cancer among black compared with white
women can be attributed to disparities in health
insurance.97
Intensive focus on modifiable system factors would
be beneficial, such as expanding insurance coverage,
addressing transportation barriers to appointments,
and increasing access to primary care. The use of
patient navigators and advocates, translator services,
and tracking systems across different health systems
could reduce the effect of limited health literacy,
mistrust, and negative prior experiences with health
care.98 General practitioners who provide counseling
and recommendations on health care preventive services can improve the rates of mammography for underscreened groups, such as recent immigrants.99
Bias by health care providers and health systems
leading to disparate rates of services offered to
patients should be corrected, and to further decrease
differences in mortality, emphasis should be placed on
ensuring equal treatment after diagnosis.100 Groups
such as the Black Women’s Health Imperative are at
the forefront of working to reduce these disparities,
and can serve as a resource for both patients and
health care providers. Efforts to promote quality
improvement and adherence to national guidelines
are important.
Breast cancer incidence is higher in younger
African American women and other ethnic groups.
In contrast, among postmenopausal women, breast
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Fig. 1. Breast-cancer-specific mortality by race over time.*SEER incidence and U.S. death ratesa, cancer of the female
breast. Joinpoint analyses for whites and blacks from 1975 to 2016 and for Asian/Pacific Islanders, American Indians/Alaska
Natives and Hispanics from 2000 to 2016. Source: Incidence data for whites and blacks are from the SEER 9 areas (San
Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas, San Jose-Monterey, Los
Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia
excluding ATL/RG, Idaho, New York and Massachusetts). Mortality data are from U.S. Mortality Files, National Center for
Health Statistics, CDC. aRates are age-adjusted to the 2000 U.S. Std Population (19 age groups—Census P25-1103).
Regression lines are calculated using the Joinpoint Regression Program Version 4.7, February 2019, National Cancer
Institute. Joinpoint analyses for Whites and Blacks during the 1975–2015 period allow a maximum of 5 joinpoints. Analyses
for other ethnic groups during the period 1992–2015 allow a maximum of 4 joinpoints. bAPI5Asian/Pacific Islander. cAI/
AN5American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the Purchased/Referred Care
Delivery Area (PRCDA) counties. dHispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and
American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska
Native Registry. *Mortality decreased over time for white and black women, with overall higher mortality for black women.
Reprinted from Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al, editors. SEER Cancer Statistics Review,
1975–2016. Bethesda, MD: National Cancer Institute; 2019. Available at: https://seer.cancer.gov/csr/1975_2016. Retrieved
October 21, 2019.
Chelmow. Early-Onset Breast Cancer Executive Summary. Obstet Gynecol 2020.

cancer incidence is highest in white women. The
proportion of breast cancer diagnoses by age for
nonwhite patients with breast cancer peaks in the late
40s, whereas diagnosis for white patients peaks in
their 60s; this phenomenon is known as the crossover
effect (Fig. 2).101
Most breast cancer research has been conducted
on white women. Major professional society screening
guidelines developed using this body of evidence
might not be adequate for nonwhite populations. No
national guidelines address this concern, but in 2018,
the American College of Radiology commented that
women at high risk, particularly black women and
those of Ashkenazi Jewish descent, should be evaluated early in life to discuss potential benefit from
supplemental screening.102 Consideration should be
given to encouraging screening before age 50 years,
especially for African American women (see Appen-
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dix 7, available online at http://links.lww.com/AOG/
B870, for complete evidence summary).

RISK-ASSESSMENT TOOLS
Although there are no validated tools or best practices
specific to identifying risk factors or estimating the
risk of early-onset breast cancer, there are multiple
tools that may be helpful to identify short-term risk in
younger women. Current best practices aim to
identify women at risk of familial cancer syndromes
on the basis of family history to determine who may
benefit from genetic testing.
The three most widely used tools for predicting
BRCA gene carrier probability are BRCAPRO, BOADICEA (the Breast and Ovarian Analysis of Disease
Incidence and Carrier Estimation Algorithm), and
Penn II.103 BRCAPRO and BOADICEA also provide cancer risk estimates in addition to estimates of
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Fig. 2. The cross-over effect: age at
diagnosis for women with breast
cancer, by race.* *The proportion of
breast cancer diagnoses by age for
nonwhite patients with breast cancer
peaks in the late 40s, while diagnosis
of white patients peaks in their 60s.
Reproduced with permission from
JAMA Surg 2018;153(6):594–595.
2018 American Medical Association. All rights reserved.
Chelmow. Early-Onset Breast Cancer
Executive Summary. Obstet Gynecol
2020.

likelihood of genetic mutations. These models might
be useful to direct women to genetic testing and counseling who are at increased risk of genetic mutations
that pose a high risk of early-onset disease. BRCAPRO is a validated statistical program to estimate individual carrier probabilities on the basis of family
history. It is not specific to any age range and does
not directly estimate the risk of early-onset cancer, but
rather the risk of carrying a BRCA1 or BRCA2 mutation. BOADICEA likewise was developed using population data from families in the United Kingdom to
create a model based on family history and requires
detailed family pedigree. The Penn II model uses clinical questions based on family history to reach a carrier
probability, but does not calculate cancer risks. Once
a BRCA1 or BRCA2 mutation is identified the Stanford
risk-assessment tool for BRCA carriers may aid in
decision making for preventive measures based as it
provides age-related risk of cancer and compares multiple intervention strategies.104
Additional widely validated models to assess
cancer risk include the Tyrer-Cuzick, modified Gail,
and Breast Cancer Surveillance Consortium models.
None specifically assess risk of early-onset or premenopausal breast cancer, although most provide
estimated 5- or 10-year cancer risk as well as lifetime
risk of breast cancer. No models used validation
cohorts with patients younger than 20 years. The
modified Gail model has been validated in women 35
years and older to assess 5-year invasive cancer
risk.105 The Tyrer-Cuzick model has been studied in
women older than age 20 years to assess 10-year can-
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cer risk and has been shown to perform better in
women with a family history of breast cancer.106
The Breast Cancer Surveillance Consortium risk calculator is validated for women older than age 35 years
to provide 5- and 10-year risks and includes family
history factors as well as breast density in the calculation.107 There are limited data on the use of these
models to specifically address cancer risk reduction
in young women.
Family history should be collected and updated
periodically to identify patients who may be at
increased risk of predisposing genetic mutations.
Tools that may aid in collecting family history are
the Ontario Family History Assessment Tool, Manchester Scoring System, Referral Screening Tool,
Pedigree Assessment Tool, and FHS-7.12,13 There is
no evidence to recommend one method over another.
Those who screen positive or who meet published
guidelines for qualifying family histories should be
referred for genetic counseling and testing.13
There are no guidelines or best practices for
identifying risk factors or for the use of tools to
estimate risk specific to early-onset breast cancer.
However, multiple organizations provide guidance
for assessing risk of breast cancer in general.
The U.S. Preventive Services Task Force advocates use of brief familial assessment tools to assess
women with a personal or family history of breast,
ovarian, tubal, or peritoneal cancer or who have an
ancestry associated with BRCA1 or BRCA2 gene mutations. The U.S. Preventive Services Task Force reviewed six tools that were adequately validated, but
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found insufficient evidence to recommend one tool
over another.12 Other organizations likewise do not
advocate for use of any specific tool.14,108–111
National Comprehensive Cancer Network guidelines on breast cancer risk reduction recommend
assessing family history and referring to genetic
counseling when appropriate as well as use of the
modified Gail or Tyrer-Cuzick model to assess risk
among women older than age 34 years.112 The
National Comprehensive Cancer Network has also
established criteria for genetic testing for high-risk
mutations.13 These guidelines recommend assessment
no earlier than age 18 years based on family history.
No specific tool is recommended, and the recommendations are not specific to reducing the risk of earlyonset cancer (see Appendix 8, available online at
http://links.lww.com/AOG/B871, for complete evidence summary).

COMMUNICATING RISK
Shared decision making is a key component of
patient-centered health care, particularly because
there is often more than one option for screening.
Although patient decision aids and risk calculators
help enumerate risk and are adjuncts to shared
decision making, the process is more involved.113
Using narrative risk communication strategies,114
communicating absolute rather than RR,115 and managing framing bias116 are important considerations in
communicating risk of early-onset breast cancer.
Many decision aids and calculators are directed to
specific populations (eg, subtypes or age ranges), but
none are specific for communicating risk of earlyonset breast cancer. Several tools may be useful:
• Families Sharing Health Assessment and Risk
Evaluation (Families SHARE, a product of the
National Institutes of Health’s National Human
Genome Research Institute) is a decision aid that is
useful for shared decision making for individuals of
varied age groups and can be used within and outside of an office setting.117
• Breast Screening Decisions (developed collaboratively by the Weill Cornell Medical College and
Sloan Kettering Cancer Center) is directed to
women aged 40–49 years.118
• Breast Cancer Screening (PDQ) has both a patient
and health care provider tool, which can be used as
companion documents.119
• The University of Wisconsin School of Public
Health’s Health Decision tool was originally created
and tested at the University of California, San
Francisco.120–122 It includes a breast cancer screen-
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ing module that can be integrated into some electronic health record systems.
Studies of decision aids for breast cancer prevention in BRCA1 and BRCA2 mutation carriers demonstrated that cancer-related distress was reduced
among those who used a decision aid compared with
those who did not. Decisional conflict did not change
with use of the aid.123,124 The following tools may be
useful for women at high risk of hereditary breast and
ovarian cancer:
• The Cancer Risk Education Intervention Tool is
a web-based (noninteractive) adjunctive tool for use
in low socioeconomic settings and among ethnically
diverse women.125
• The Stanford Shared Decision Making Tool for
women with BRCA1 or BRCA2 was developed to
guide decision making about screening and treatment based on calculated risk.104
For minority groups, the Health Belief Model was
used as a construct for developing a school-based
classroom and online tool that increased knowledge
about breast cancer risk among African American
women aged 20–39 years.126
Because we anticipated that a literature search
would find limited information specific to communicating risk of early-onset breast cancer, we deliberately conducted a broad search encompassing other
aspects of breast cancer and other cancers and health
conditions. Patient decision aids for colorectal cancer
screening have been shown to improve knowledge
and interest in screening compared with no information, but are no better than general colorectal cancer
screening information.127 Healthwise Knowledge
Base is an evidence-based interactive platform to
inform patients about mammogram initiation that includes a shared decision making breast cancer screening tool for women aged 40–50 years (see Appendix
9, available online at http://links.lww.com/AOG/
B872), as well as a tool for assisting in decisions about
BRCA testing. The user’s concerns, desires, and fears
are weighed in response to evidence provided about
the risks and benefits of screening, and a score indicating preferences and readiness for screening is calculated.128 A decision analytic model was used to
improve estimation of benefits and risks for patients
undergoing thrombolysis, with the added benefit that
this computerized decision aid can be embedded in an
electronic health record.129 This approach could be
translated to support integration of the Gail or Families SHARE model, for example, into a primary care
or a woman’s personal electronic health record.
There are no current major professional society
or health services guidelines about communicating the
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risk for early-onset breast cancer. Shared decision
making has been endorsed by ACOG for deciding the
age at which to initiate breast cancer screening.109 The
American College of Obstetricians and Gynecologists
acknowledges the importance of screening for social
determinants of health in all patients, as these factors
may influence decision making and communication.86
U.S. Preventive Services Task Force guidelines
do not address early-onset breast cancer risk, except
to state that the recommended screening guidelines do
not apply to women with prior chest radiation or
known underlying genetic mutations such as BRCA1
or BRCA2. National Institute of Health Care Excellence guidelines recommend providing information
and support for decision making, but do not recommend any specific tool or decision aid. National Institute of Health Care Excellence guidelines regarding
familial breast cancer also recommend the use of
shared decision making, materials, and decision aids
as well as standardizing the discussion involved in
counseling patients and families at risk for familial
breast cancers108 (see Appendix 9 [http://links.lww.
com/AOG/B872] for complete evidence summary).

RISK-REDUCTION STRATEGIES
There is limited evidence for risk modification specific
to the outcome of early-onset breast cancer. The
evidence for risk reduction among younger women
is most robust for BRCA mutation carriers.
Risk-reducing bilateral mastectomy should be
considered in women with a genetic mutation conferring a high risk of breast cancer.112 There are no
guidelines or studies addressing the age at which
risk-reducing mastectomies should be undertaken.
Age-related risk estimation tables may be useful to
counsel women with BRCA mutations on the timing
of prophylactic procedures.130 There is no evidence
supporting risk-reducing mastectomies for women
with low-risk genes or whose risk is based on nonhereditary factors alone.
We found no evidence to support oophorectomy
for the purposes of preventing early-onset breast
cancer. The use of bilateral salpingo-oophorectomy
to prevent lifetime risk of breast and ovarian cancer
has been estimated to be as high as 50% for BRCA1
and BRCA2 carriers, although more recent publications question these results.131
There are no guidelines or studies about the use of
risk-reducing agents expressly for the purpose of
reducing the risk of early-onset breast cancer. Tamoxifen is the only agent indicated for use in premenopausal women at increased risk of breast cancer, and is
recommended for women with 5-year risk of 1.7% or
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higher. The risks and benefits in women younger than
35 years is not known.112 Most large trials of chemoprevention were performed in older women who had
completed menopause. The National Surgical Adjuvant Breast and Bowel Project P-1 trial found a 44%
decrease in cancer among women younger than 50
years treated with tamoxifen for chemoprevention.132
There are limited data regarding the magnitude of
risk reduction with the use of tamoxifen for BRCA1
and BRCA2 mutation carriers or women with prior
thoracic radiation. However, cohort data suggest there
might be a benefit for BRCA2 carriers; the National
Surgical Adjuvant Breast and Bowel Project P-1 study
showed a nonsignificant 62% decrease relative to placebo (RR 0.38, 95% CI 0.06–1.56).112,132 Although
other European studies have shown mixed effects, this
overall reduction is supported by a systemic review of
randomized controlled prevention trials across all
studied populations showing a 44% decrease in the
risk of breast cancer for women younger than 50 (hazard ratio 0.66, 95% CI 0.52–0.85).133
There is limited evidence for the modification of
health behaviors to reduce the risk of early-onset breast
cancer. A recent meta-analysis assessed numerous risk
factors for BRCA carriers.134 Later age at the time of
first live birth was associated with a decreased lifetime
risk of breast cancer for BRCA1 carriers (effect size for
women aged 30 years or older50.65 vs women aged
younger than 30 years, 95% CI 0.42–0.99). There was
no effect of age at first birth for BRCA2 carriers.
Breastfeeding also appeared protective for lifetime risk of cancer for BRCA1 carriers, although metaanalysis could not be performed because of study heterogeneity. Reported effects based on case–control
studies showed a 32–50% decreased risk if breastfeeding continued for more than 1 year compared
with never breastfeeding. Additionally, three or more
live births also appeared to have a protective effect for
BRCA1 carriers (effect size50.57, 95% CI 0.39–0.85)
as well as BRCA2 carriers (effect size50.52, 95% CI
0.30–0.86), compared with nulliparity. For BRCA1 or
BRCA2 carriers, there were no significant or reliably
duplicated results of effects of alcohol consumption,
oral contraceptive use, or smoking.134,135 In review
articles on risk factors for women at average risk,
there was no reliable effect seen for alcohol consumption or modification of other dietary factors for
premenopausal breast cancer.136,137
There are no guidelines specific to the prevention
of early-onset breast cancer. Those that may be
considered relevant address lifetime breast cancer risk
reduction, largely among women older than age 35
years. The National Comprehensive Cancer Network
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recommends tamoxifen, 20 mg/d, for up to 5 years for
women aged 35 years and older with a high 5-year risk
of breast cancer, defined as a 5-year risk of 1.7% or
higher using the Gail model, or prior lobular carcinoma in situ.112 U.S. Preventive Services Task Force
guidelines for reducing the risk of primary cancer state
that women at increased risk should engage in shared
decision making regarding chemoprevention.
The National Comprehensive Cancer Network
advises a healthy lifestyle for reduction of risk for
breast cancer for all women, though the magnitude of
this reduction and whether it reduces the risk of earlyonset breast cancer or premenopausal breast cancer is
unknown.97 Elements of healthy lifestyle advised by
the National Comprehensive Cancer Network include
limited alcohol consumption, vigorous physical activity, maintaining a healthy weight, and breastfeeding
(see Appendix 10, available online at http://links.lww.
com/AOG/B873, for complete evidence summary).
Breast self-examination is no longer part of major
society guidelines for average risk women given the
high number of false positives and absence of
supportive evidence for benefit.2,12,109 Our literature
review found no evidence for its use in women at risk
for early-onset breast cancer, but women should be
counseled to be familiar with their breasts and
promptly report changes to their breasts to their
health care provider.

SPECIAL CONSIDERATIONS FOR EARLYONSET BREAST CANCER
Survivorship in women with early-onset breast cancer
is a critical component to initial evaluation and
treatment as well as ongoing care. Chemotherapy is
often and variably responsible for chemotherapyinduced amenorrhea, menopause, or true ovarian
failure, resulting in consequences such as infertility
or subfertility, bone loss, and increased cardiac risk as
well as menopausal symptoms, which can have
a significant effect on quality of life. Age at diagnosis,
receptor status, and treatment regimen are important
considerations in managing ongoing care for women
affected by early-onset breast cancer.
The National Comprehensive Cancer Network
and the American Society of Clinical Oncology have
produced comprehensive guidelines for survivorship.138,139 The American Cancer Society and the
American Society of Clinical Oncology jointly created survivorship guidelines after systematic review
in 2015.140 Although not specific for early-onset
breast cancer, ACOG provides resources about managing gynecologic issues in women with breast cancer,
many of which are applicable for women with early-
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onset breast cancer.141 The American College of Obstetricians and Gynecologists recommendations
include use of nonhormonal interventions for symptomatic patients, because data are conflicting about
the deleterious effects of hormone therapy on recurrence and overall survival rates.141 Although not specific to women with early-onset breast cancer, the
North American Menopause Society and the International Society on Women’s Sexual Health have coauthored recommendations regarding the treatment
of genitourinary syndrome of menopause in women
with breast cancer.142
Management of women who have or have had
early-onset breast cancer should include attention to
the issues of contraception, fertility, and pregnancy:
• Effective contraception is often overlooked as part
of the treatment regimen for patients with earlyonset breast cancer, and family planning consultation should be considered.143 The copper IUS is the
preferred contraceptive method for women with
breast cancer, although the levonorgestrel IUS can
safely be used in combination with tamoxifen.144,145
The preferred method of emergency contraception
is the copper-containing IUS, although progestin
regimens can also be used.146
• All women with early-onset breast cancer should have
fertility preservation counseling.147 Oocyte and
embryo cryopreservation is considered first-line treatment.147 Treatment with gonadotropin-releasing hormone agonist during chemotherapy should be
considered when ovarian oocyte and embryo cryopreservation is not possible; it affords some protection
to the ovary and is associated with increased fertility
rates when compared with no treatment.148 Aromatase
inhibitors and gonadotropin-releasing hormone agonist triggers should be used when employing controlled ovarian stimulation for women undergoing
fertility treatments with a history of early-onset breast
cancer to lower estrogen levels.149 Prenatal genetic
diagnosis should be considered in women with BRCA
mutations or other documented germ line mutations
undergoing in vitro fertilization procedures. Ovarian
tissue harvesting offers a promising alternative to
cryopreservation therapies.149
• Pregnancy after a diagnosis of early-onset breast
cancer has not been shown to increase the risk of
recurrence.150 When considering timing, pregnancy
occurring at least 10 months after breast cancer
diagnosis was not found to be harmful and may
even contribute to survivorship.151 When breast
cancer is diagnosed in pregnancy, chemotherapy
can be safely instituted in the second and third
trimesters.150
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See Appendix 1 (http://links.lww.com/AOG/
B864) for complete evidence summary.

5. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N,
Margenthaler JA. Elevated breast cancer mortality in women
younger than age 40 years compared with older women is
attributed to poorer survival in early-stage disease. J Am Coll
Surg 2009;208:341–7.

RESEARCH GAPS AND OPPORTUNITIES
The evidence review and subsequent stakeholder
discussion revealed the following research gaps and
opportunities for early-onset breast cancer (see
Appendix 11, available online at http://links.lww.
com/AOG/B874, for a more in-depth assessment):
• Develop risk-assessment tools specific to early-onset
breast cancer
• Optimize integration of risk assessment into primary
care visits and electronic health records
• Obtain data on and determine optimal screening for
nonwhite populations
• Determine risks associated with dense breasts in
young women
• Determine appropriate adjunctive screening for
young women with dense breasts
• Validate
epidemiologic data largely based on
European populations in U.S. women, including
underrepresented subgroups
• Develop strategies to eliminate implicit bias among
health care providers and medical systems
• Expand screening, genetic counseling, and testing
among high-risk women
• Develop and validate tools for communicating
early-onset breast cancer risk to patients
• Develop and validate training techniques for health
care providers to screen, test, and initiate riskreducing strategies in women at risk for early-onset
breast cancer
• Determine safety and optimal timing of pregnancy
after treatment for early-onset breast cancer
• Optimize fertility preservation in women undergoing treatment for early-onset breast cancer
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